Texas, ANI. Urinary tract infections (UTIs) are difficult to treat due to antibiotic-resistant bacteria. In such a situation, the need of the hour is to develop better treatment methods. In this direction, researchers from the University of Texas have explored the possibility of developing a new vaccine. His research has been published in the ‘ACS Nano Journal’ of the American Chemical Society.

Dr. Nicole De Nisko, Assistant Professor of Biological Sciences, and Dr. Jeremiah Gassensmith, Associate Professor of Chemistry and Biochemistry, recently demonstrated that using metal-organic frameworks (MOFs), whole cells of bacteria were collected in a small envelope. A depot can be created by inactivating it, so that the body can get the benefits of the vaccine for a long time. Around 150 million people suffer from UTI every year in the world.

This study on rats also revealed that the use of this method resulted in a significant increase in antibody production and its survival rate compared to the traditional standard whole-cell vaccine. Whole-cell vaccines are made from inactivated bacteria, in which the germs are killed by either a physical or chemical process, so that those germs cannot cause disease. De Nisco said that if antibiotics are not effective, recurrent UTIs can be prevented by vaccination. According to him, due to non-killing of bacteria from antibiotics or severe allergic reactions to antibiotics, there is a lot of damage to the bladder of patients especially the elderly. Once the bacteria have been eliminated from the bladder, they still remain elsewhere and gradually become antibiotic resistant.

Gassensmith said that from 2018 onwards, we thought of storing antigen in this depot or store and making it a better whole-cell vaccine, which is slowly synthesized. Vaccines usually use weakened or dead disease-causing bacteria or small components of them. The antibodies produced by it prevent any one disease. But making an anti-bacterial vaccine is more complicated than developing an anti-virus vaccine, because the size of the bacteria is larger. So it is difficult to choose any one ingredient of it. For this reason it was preferable to select whole bacteria. But one problem with the whole-cell bacterial vaccine is that it does not provide enough immunity to the body for a long period of time. That’s why they created the MOF Antigen Depot, which keeps dead pathogens in the tissues for a longer period of time and provides complete immunity when infection occurs.

The new vaccine will cure.

What is a metal-organic framework

The research team deposited a specific type of bacterial cell in a metal-organic framework consisting of crystalline polymeric matrices. It not only kills bacteria, but also keeps those dead cells stable by protecting them from high temperatures, moisture and organic solvents. The researchers used strains of E. coli bacteria during their experiment. There is currently no vaccine for any pathogenic strain of this bacteria, and this bacteria affects up to 80 percent of patients. When mice were injected with this bacteria after the newly developed vaccine, the new vaccine was more effective than the conventional vaccine.

Edited By: Neel Rajput